Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors

Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially availableAchieved Gross Revenue Target In Fourth Quarter 2020, Reflecting Initial Stocking of TwirlaA® (levonorgestrel and ethinyl estradiol) transdermal systemAnnounces Agreement with Sterling Specialty Pharmacy PRINCETON, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.A (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and twelve months endedA December 31, 2020 and provided a corporate update.a??We closed out 2020 on a high note with the commercial launch of TwirlaA® in December, following the approval by the U.S. Food and Drug Administration. Supported by the tireless efforts of the entire Agile team, a dedicated sales force and broad wholesaler relationships, we shipped commercial product to wholesalers in our targeted time frame and we believe we are now well-positioned to continue our early launch momentum with strong interest continuing to support Twirlaa??s growth,a?? said Al Altomari, Chairman and Chief Executive Officer of Agile. a??We continue to be optimistic about Twirlaa??s trajectory, which we expect to be further supported by our new partnership with Sterling Specialty Pharmacy and bolstered by the increased flexibility from the remaining $25 million potentially available from Perceptive Advisors.a??
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »